News

Sanofi ramps up artemisinin plant
Enlarge image

BusinessItalyFranceBulgaria

Sanofi ramps up artemisinin plant

12.04.2013 - From its Italian manufacturing site at Garessio, Sanofi has launched large-scale production of semi-synthetic artemisinin, a potent anti-malarial drug.

The launch of the new facility on April 11 represents a further milestone in an anti-malarial drug partnership led by OneWorld Health, a non-profit drug development organisation, with funding from the Bill & Melinda Gates Foundation. Sanofi has invested €10m to build an industrial-scale plant that converts the biological precursor artemisinic acid into artemisinin in reaction steps that involve photochemistry. With its photochemical batch-flow-reactor technology in action, Sanofi envisions a production of 35 tonnes of semi-synthetic artemisinin in 2013, with the first batches available by this summer. It plans to increase capacity to 60 tonnes per year in 2014 and thereafter, which would meet at least a third of the annual global need for the drug. Sanofi hopes to get WHO approval for its product in the coming weeks.

From a technology perspective, the semi-synthetic artemisinin project is a combination of biotechnological and chemical know-how at the industrial scale. Artemisinin is a secondary metabolite extracted from the traditional Chinese medical herb Artemisia annua. However, the botanical supply is subject to climatic variables, leading to a fluctuation in antimalarial medicines and big price variations. Aiming for a stable and more reliable supply of the drug, Jay Keasling and his team at the University of California Berkeley and synthetic biology start-up Amyris genetically engineered yeast cells to produce the precursor artemisinic acid, which must then be converted into artemisinin by synthetic organic chemistry. Sanofi entered the project in 2008 as manufacturing partner with its Access to Medicines programme, and was involved in scaling-up fermentation of artemisinic acid and its conversion into artemisinin using photochemistry. At a facility run by Huverpharma in Bulgaria, an industrial-scale fermentation process was established that could produce up to 100 tonnes of artemisinic acid annually. It is considered as the first industrial-scale deployment of synthetic biology for drug production. Sanofi said it will provide its semi-synthetic artemisinin at a stable price using a non-profit, non-loss production model.

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/sanofi-ramps-up-artemisinin-plant.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%

FLOP

  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%

TOP

  • WILEX4.20 EUR418.5%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%

FLOP

  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 23.05.2015